CSE:AGN - Post Discussion
Post by
XeniaTechie on Apr 21, 2023 11:37am
AGN receives US patent for CKD drug
Algernon Pharmaceuticals Inc.has received a Notice of Allowance from the United States Patent and Trademark Office for its lead drug NP-251 (Repirinast), a promising candidate for treating chronic kidney disease and non-alcoholic fatty liver disease. Repirinast was previously marketed by Mitsubishi Tanabe Pharma to treat asthma, and Algernon has since obtained a supply from a Chinese manufacturer. Preclinical studies have shown Repirinast to reduce hepatic fibrosis by 57% and the NAFLD score by 31%, making it a strong candidate for treatment. Algernon's patent applications protect their intellectual property strategy. https://financialpost.com/globe-newswire/algernon-pharmaceuticals-announces-notice-of-allowance-for-method-of-use-u-s-patent-application
Be the first to comment on this post